ERBB2 and breast carcinoma: Treatment with metformin reportedly caused suppression of tumor angiogenesis by targeting the human epidermal growth factor receptor-2 /hypoxia inducible factor-1 alpha/VEGF (HER2/HIF-1α/VEGF) secretion axis in different breast cancer cell lines [53].